Anti-Scarring Gene Therapy Platform
Pulmonary Fibrosis/Infections, Burn Injuries, Surgical Adhesions, Traumatic Brain Injury
Pre-clinicalActive
Key Facts
Indication
Pulmonary Fibrosis/Infections, Burn Injuries, Surgical Adhesions, Traumatic Brain Injury
Phase
Pre-clinical
Status
Active
Company
About Cellastra
Cellastra is an early-stage biotech focused on a significant unmet need: preventing pathological scarring and fibrosis. The company's core technology involves using AAV vectors to deliver the gene for Ensereptide, an anti-scarring peptide, directly to injury sites to promote scar-free healing. Led by a seasoned team with deep drug development and regulatory experience, Cellastra is currently seeking investors and development partners to advance its pipeline. Its initial targets include pulmonary fibrosis, burn injuries, and post-surgical adhesions.
View full company profile